NCT04564703: EMN26 Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
- Active, not recruiting
- Dec 9, 2020
- 1 min read
Updated: Feb 10, 2024
EMN26
NCT04564703: Phase 2: Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenance treatment after transplant.
Sponsor
Collaborators
Celgene Corporation
Healt Data Specialists - HeaDS (CRO)
EMN Research Italy Impresa Sociale Srl
Location
Europe
ClinicalTrials.gov Identifier: NCT04564703
Official Title: Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients
First Posted: September 25, 2020
Click here for details on Clinicaltrials.gov
Drug: Iberdomide
Locations
Europe
France
Greece
Italy
Netherlands
